Ligand Pharma (LGND) Tops Q4 EPS by 9c ; Offers Guidance
Get Alerts LGND Hot Sheet
Price: $322.75 +1.71%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.27, $0.09 better than the analyst estimate of $1.18. Revenue for the quarter came in at $42.81 million versus the consensus estimate of $39.03 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $6.00-$6.25, versus the consensus of $6.14. Ligand Pharma sees FY2025 revenue of $180-200 million, versus the consensus of $188.8 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- New Break Resources plans $550,000 flow-through share offering
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share